{
  "items": [
    {
      "title": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
      "description": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
      "published_utc": "2025-05-26T08:07:14",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce",
      "category": "company",
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453973904/image_1453973904.jpg?io=getty-c-w1536",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134697300,
      "datetime": 1748218034
    }
  ]
}